Search results for "prognostic marker"

showing 5 items of 5 documents

Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia

2008

Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgVH mutational status, widely differing clinical courses were revealed. Since IgVH sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgVH mutational status seems an important priority. In the present study, we proposed the use of Cryptochrome- 1 as a new prognostic marker in early-stage chronic lymphocytic leukemia. Seventy patients (Binet stage A, without treatment) were included in the study. We correlated Cryptochrome-1 mRNA with well established prognostic markers such as IgVH mu…

Oncologymedicine.medical_specialtyChronic lymphocytic leukemiaIgV(H)ZAP70 LPL IgVHImmunoglobulin E:CIENCIAS MÉDICAS ::Patología::Hematología [UNESCO]Prognostic markerPredictive Value of TestsInternal medicinemedicineHumansUNESCO::CIENCIAS MÉDICAS ::Patología::HematologíaRNA MessengerStage (cooking)HematologybiologyFlavoproteinsZAP70CancerHematologyCryptochrome-1medicine.diseasePrognosis:CIENCIAS MÉDICAS [UNESCO]Leukemia Lymphocytic Chronic B-CellCryptochromesLeukemiaUNESCO::CIENCIAS MÉDICAS ::Patología::OncologíaImmunologyUNESCO::CIENCIAS MÉDICASbiology.proteinZAP70Brief ReportsChronic lymphocytic leukemiaAntibodyLPL:CIENCIAS MÉDICAS ::Patología::Oncología [UNESCO]BiomarkersCryptochrome-1 ; Prognostic marker ; Chronic lymphocytic leukemia ; ZAP70 LPL IgVH
researchProduct

Prognostic Value of Complement Properdin in Cancer

2021

© 2021 Mangogna, Varghese, Agostinis, Alrokayan, Khan, Stover, Belmonte, Martorana, Ricci, Bulla and Kishore. The complement system is readily triggered by the presence of damage-associated molecular patterns on the surface of tumour cells. The complement alternative pathway provides rapid amplification of the molecular stress signal, leading to complement cascade actvation to deal with pathogens or malignant cells. Properdin is the only known positive regulator of the alternative pathway. In addition, properdin promotes the phagocytic uptake of apoptotic T cells by macrophages and dendritic cells without activating the complement system, thus, establishing its ability to recognize “altered…

Malelcsh:Immunologic diseases. Allergybioinformatics analysisNeutrophilsComplement Pathway AlternativeImmunologyDatasets as TopicInflammationchemical and pharmacologic phenomenaBiologyLymphocytes Tumor-InfiltratingImmune systemNeoplasmsTumor Microenvironmentmedicinebioinformatics; cancer; complement; innate immunity; prognosis; properdinData MiningHumansImmunology and AllergyCytotoxic T cellcancercomplementRNA MessengerRNA Neoplasminnate immunityOriginal ResearchTumor microenvironmentInnate immune systembioinformaticMacrophagesDendritic CellsbioinformaticsLymphocyte SubsetsComplement systemproperdinAlternative complement pathwayCancer researchProperdinFemaleprognosismedicine.symptomTranscriptomelcsh:RC581-607prognostic markerprognosi
researchProduct

Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long…

2020

Introduction: Surgical procedure is the treatment of choice in early stage I lung adenocarcinoma. However, a considerable number of patients experience recurrence within the first 2 years after complete resection. Suitable prognostic biomarkers that identify patients at high risk of recurrence (who may probably benefit from adjuvant treatment) are still not available. This study aimed at identifying methylation markers for early recurrence that may become important tools for the development of new treatment modalities. Methods: Genome-wide DNA methylation profiling was performed on 30 stage I lung adenocarcinomas, comparing 14 patients with early metastatic recurrence with 16 patients with …

0301 basic medicinePulmonary and Respiratory MedicineOncologyLung adenocarcinomamedicine.medical_specialtyLung NeoplasmsADNAdenocarcinoma of LungMethylation profilingmedicine.disease_causeMethylation03 medical and health sciences0302 clinical medicinePrognostic markerPLUTInternal medicineBiomarkers TumorHumansMedicineddc:610Promoter Regions Geneticbusiness.industryHazard ratioPromoterMethylationDNADNA MethylationPrognosismedicine.diseaseLong non-coding RNA030104 developmental biologyDifferentially methylated regionsOncology030220 oncology & carcinogenesisIncRNACàncer de pulmóBiomarker (medicine)AdenocarcinomaRNA Long NoncodingNeoplasm Recurrence LocalLung cancerbusinessCarcinogenesisMetilació
researchProduct

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

2022

Abstract Background Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status, but their effects on resectability and conversion rates have not been extensively studied. Methods This substudy of the prospective RAXO trial included 906 patients recruited between 2011 and 2018. We evaluated repeated centralised resectability assessment, conversion/resection rates and overall survival (OS), according to RAS and BRAF status. Results Patients included 289 with RAS and BRAF wild-type (RAS and BRAFwt), 529 with RAS mutated (RASmt) and 88 with BRAF mutated (BRAFmt) mCRC. Metastatic prevalence varied between the RAS and BRAFwt/RASmt/BRAFmt groups,…

Proto-Oncogene Proteins B-rafCancer ResearchBEVACIZUMAB3122 Cancerscolorectal cancerbiomarkkerit3121 Internal medicineleikkaushoitoLIVER METASTASESetäpesäkkeetsurgical oncologyKRASHumansmetastasisProspective StudiesFOLFOXIRIpaksusuolisyöpäCancer och onkologiRectal NeoplasmsCOLON-CANCERMetastasectomyennusteetCHEMOTHERAPYOncologysyöpägeenithoitotuloksetCancer and OncologyColonic NeoplasmsMutationSURVIVALsyöpätauditonkologiaColorectal Neoplasmsprognostic markers
researchProduct

Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer

2023

Abstract Background The CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint interaction may promote cancer progression, but the expression patterns and prognostic significance of PD-L1 and PD-1 in the colorectal cancer microenvironment are inadequately characterised. Methods We used a custom 9-plex immunohistochemistry assay to quantify the expression patterns of PD-L1 and PD-1 in macrophages, T cells, and tumour cells in 910 colorectal cancer patients. We evaluated cancer-specific mortality according to immune cell subset densities using multivariable Cox regression models. Results Compared to PD-L1– macrophages, PD-L1+ macrophages were more likely M1-polarised than M2-polarised and located close…

Cancer ResearchkasvaimetOncologyimmunologiaimmuunijärjestelmätumour immunology3122 Cancerscolorectal cancersyöpätauditsuolistosyövät3121 Internal medicineprognostic markerscancer microenvironment
researchProduct